Claims

WHAT IS CLAIMED IS:

- 1. A method for producing stable cell lines of mammalian neural precursor cells *in vitro*, comprising the steps of:
 - a) preparing a culture of neural precursor cells in a serum-free medium;
- b) culturing the neural precursor cells in the presence of a first mitogen, wherein said first mitogen is selected from the group consisting of aFGF, bFGF, EGF, TGF α and combinations thereof;
- c) contacting the cells with an agent capable of being taken up by the cells and capable of expressing a c-myc gene; and
- d) further culturing the cells in a medium containing the first mitogen and a second mitogen, wherein said second mitogen is selected from the group consisting of aFGF, bFGF, EGF, $TGF\alpha$, serum and combinations thereof, with the proviso that the second mitogen is other than the first mitogen.
- 2. The method of claim 1, wherein the c-myc gene is fused with other DNA elements, wherein said other DNA elements comprise at least one element selected from the group consisting of a ligand binding domain for an estrogen receptor, an androgen receptor, a progesterone receptor, a glucocorticoid receptor, a thyroid hormone receptor, a retinoid receptor, and an ecdysone receptor.

- 3. The method of claim 1, wherein said medium containing the first mitogen and the second mitogen further comprises a myc-activating chemical selected from the group consisting of β -estradiol, RU38486, dexamethasone, thyroid hormones, retinoids, and ecdysone.
- 4. The method of claim 1, wherein the mammalian neural precursor cells are derived from a human.
- 5. The method of claim 1, wherein the mammalian neural precursor cells are derived from an *in vitro* culture of pluripotent embryonic stem cells.
 - 6. A cell line produced according to the method of claim 1.
- 7. The cell line of claim 6, wherein the cells maintain a multipotential capacity to differentiate into neurons, astrocytes and oligodendrocytes.
- 8. The cell line of claim 6, wherein the cells maintain a bipotential capacity to differentiate into neurons and astrocytes.
- 9. The cell line of claim 6, wherein the cells maintain a bipotential capacity to differentiate into astrocytes and oligodendrocytes.

- 10. The cell line of claim 6, wherein the cells maintain a unipotential capacity to differentiate into neurons.
- 11. The cell line of claim 6, wherein the cells maintain a unipotential capacity to differentiate into astrocytes.
- 12. A method for producing stable clonal cell lines of mammalian neural precursor cells *in vitro*, comprising the steps of:
 - a) preparing a culture of neural precursor cells in a serum-free medium;
- b) culturing the neural precursor cells in the presence of a first mitogen, wherein said first mitogen is selected from the group consisting of aFGF, bFGF, EGF, TGF α and combinations thereof;
- c) contacting the cells with an agent capable of being taken up by the cells and capable of expressing a c-myc gene and a selectable marker;
- d) further culturing the cells in a medium containing the first mitogen and a second mitogen, wherein said second mitogen is selected from the group consisting of aFGF, bFGF, EGF, $TGF\alpha$, serum and combinations thereof, with the proviso that the second mitogen is other than the first mitogen; and
- e) collecting c-myc treated cells and co-culturing them with feeder cells free of the selectable marker and capable of supporting survival of the c-myc treated cells in a medium containing the first mitogen and the second mitogen, with the proviso that the second mitogen is other than the first mitogen.

- 13. The method of claim 12, wherein the c-myc gene is fused with other DNA elements, wherein said other DNA elements comprise at least one element selected from the group consisting of a ligand binding domain for an estrogen receptor, an androgen receptor, a progesterone receptor, a glucocorticoid receptor, a thyroid hormone receptor, a retinoid receptor, and an ecdysone receptor.
- 14. The method of claim 12, wherein said medium containing the first mitogen and the second mitogen further comprises a myc-activating chemical selected from the group consisting of β -estradiol, RU38486, dexamethasone, thyroid hormones, retinoids, and ecdysone.
- 15. The method of claim 12, wherein the mammalian neural precursor cells are derived from a human.
- 16. The method of claim 12, wherein the mammalian neural precursor cells are derived from an *in vitro* culture of pluripotent embryonic stem cells.
 - 17. A cell line produced according to the method of claim 12.
- 18. The cell line of claim 17, wherein the cells maintain a multipotential capacity to differentiate into neurons, astrocytes and oligodendrocytes.

- 19. The cell line of claim 17, wherein the cells maintain a bipotential capacity to differentiate into neurons and astrocytes.
- 20. The cell line of claim 17, wherein the cells maintain a bipotential capacity to differentiate into astrocytes and oligodendrocytes.
- 21. The cell line of claim 17, wherein the cells maintain a unipotential capacity to differentiate into neurons.
- 22. The cell line of claim 17, wherein the cells maintain a unipotential capacity to differentiate into astrocytes.